Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Madrigal Pharmaceuticals Inc (MDGL)  
$308.59 21.07 (7.33%) as of 4:30 Wed 7/9


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 25,710,000
Market Cap: 7.93(B)
Last Volume: 9,322,967 Avg Vol: 9,248,166
52 Week Range: $202.48 - $355.88
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Diagnostic Substances

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 424,685
Total Buy Value $0 $0 $0 $77,751,391
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 10
Total Shares Sold 0 60,368 84,419 381,986
Total Sell Value $0 $20,754,419 $28,104,803 $100,453,455
Total People Sold 0 8 10 12
Total Sell Transactions 0 15 21 46
End Date 2025-04-10 2025-01-07 2024-07-09 2023-07-10

   
Records found: 228
  Page 1 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bate Kenneth Director   –       •      –    2025-06-20 4 A $0.00 $0 D/D 715 2,627     -
   Daly James M Director   –       •      –    2025-06-20 4 A $0.00 $0 D/D 715 2,627     -
   Baker Julian   –       •      –    2025-06-20 4 A $0.00 $0 I/I 2,860 1,796,261     -
   Fouse Jacqualyn A Director   –       •      –    2025-06-20 4 A $0.00 $0 D/D 203 1,097     -
   Friedman Paul A Director   –       •      –    2025-06-20 4 A $0.00 $0 D/D 715 187,164     -
   Levy Richard S Director   –       •      –    2025-06-20 4 A $0.00 $0 D/D 715 21,197     -
   Soergel David Chief Medical Officer   •       –      –    2025-05-15 4 A $0.00 $0 D/D 7,545 7,545     -
   Levy Richard S Director   –       •      –    2025-04-10 4 OE $65.06 $616,118 D/D 9,470 20,482     -
   Dier Mardi SVP and CFO   •       –      –    2025-03-10 4 AS $323.04 $83,344 D/D (258) 10,440 -9%     
   Fouse Jacqualyn A Director   –       •      –    2025-03-10 4 A $0.00 $0 D/D 894 894     -
   Taub Rebecca Pres., R&D, and CMO   •       •      –    2025-03-05 4 A $0.00 $0 D/D 4,382 461,044     -
   Sibold William John President and CEO   •       •      –    2025-03-05 4 A $0.00 $0 D/D 13,066 117,369     -
   Dier Mardi SVP and CFO   •       –      –    2025-03-05 4 A $0.00 $0 D/D 3,784 10,698     -
   Waltermire Robert E. Senior VP, Chief Pharma Dev.   •       –      –    2025-03-05 4 A $0.00 $0 D/D 2,061 5,789     -
   Waltermire Robert E. Senior VP, Chief Pharma Dev.   •       –      –    2025-03-05 4 S $335.15 $4,817,104 D/D (14,113) 3,728 11%     
   Waltermire Robert E. Senior VP, Chief Pharma Dev.   •       –      –    2025-03-05 4 OE $87.09 $1,234,766 D/D 14,113 17,841     -
   Kelley Shannon T General Counsel   •       –      –    2025-03-05 4 A $0.00 $0 D/D 3,187 10,477     -
   Huntsman Carole Chief Commercial Officer   •       –      –    2025-03-05 4 A $0.00 $0 D/D 3,386 11,990     -
   Huntsman Carole Chief Commercial Officer   •       –      –    2025-03-03 4 AS $313.08 $597,840 D/D (1,834) 8,604 -5%     
   Dier Mardi SVP and CFO   •       –      –    2025-03-03 4 AS $323.54 $637,248 D/D (1,961) 6,914 -5%     
   Kelley Shannon T General Counsel   •       –      –    2025-03-03 4 AS $335.00 $139,025 D/D (415) 7,290 -5%     
   Waltermire Robert E. Senior VP, Chief Pharma Dev.   •       –      –    2025-02-28 4 S $340.99 $418,488 D/D (1,227) 3,728 10%     
   Daly James M Director   –       •      –    2025-02-27 4 S $346.90 $5,375,126 D/D (15,470) 1,912 8%     
   Daly James M Director   –       •      –    2025-02-27 4 OE $65.06 $1,282,478 D/D 15,470 17,382     -
   Sibold William John President and CEO   •       •      –    2025-02-27 4 OE $0.00 $0 D/D 50,000 104,303     -

  228 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed